The intravenous formulation of paclitaxel has been added to the EML in 2011 and used since in the treatment protocols for many cancers. This new mode of administration, without new requirement for diagnostics, makes the indication promising for LMIC settings pending their approval by recognised SRA (Stringent Regulatory Authorities), and therefore have been included in the watchlist.